Cargando…
Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells
BACKGROUND: Cisplatin is one of the most widely used chemotherapeutic agents, but its efficacy is limited by its side effects. Hence, it is of great significance to develop novel agents to synergize with cisplatin and decrease side effects. In our previous study, we demonstrated that WZ35, a novel c...
Autores principales: | He, Wei, Xia, Yiqun, Cao, Peihai, Hong, Lin, Zhang, Tingting, Shen, Xin, Zheng, Peisen, Shen, Huanpei, Liang, Guang, Zou, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528260/ https://www.ncbi.nlm.nih.gov/pubmed/31113439 http://dx.doi.org/10.1186/s13046-019-1215-y |
Ejemplares similares
-
Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells
por: Chen, Xi, et al.
Publicado: (2018) -
Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors
por: Xia, Yiqun, et al.
Publicado: (2021) -
Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer
por: Zhang, Haiyong, et al.
Publicado: (2021) -
Retraction Note: Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer
por: Zhang, Haiyong, et al.
Publicado: (2022) -
To inhibit TrxR1 is to inactivate STAT3–Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors
por: Busker, Sander, et al.
Publicado: (2020)